Top medical breakthroughs of 2025

Looking back at 2025 from a clinician’s perspective, one theme is unavoidable: evidence has begun to accumulate in fields that, until recently, appeared far from real-world translation. At the same time, some long-standing clinical needs - metabolic disease, viral prevention, rare conditions - have finally seen credible progress supported by high-quality trials. Below are ten advances that, for different reasons, stand out.

Instead of presenting a simple countdown of “discoveries,” this overview explores why certain findings truly matter for clinical practice. Some are ready for immediate implementation; others are early signals of what may become mainstream within a decade. Taken together, they depict a future in which precision, prevention, and biological engineering converge to reshape the care we deliver.

1. Twice-yearly lenacapavir: HIV prevention enters a new era

Few findings this year have the immediacy and public-health impact of the PURPOSE trials. The demonstration that lenacapavir, administered only twice a year, can provide robust HIV pre-exposure prophylaxis marks a pivotal shift in prevention strategy.

For clinicians working with populations where adherence to daily oral PrEP is challenging, the practical implications are immense. The New England Journal of Medicine data showed high efficacy across diverse groups, including men, transgender people, and gender-diverse individuals (groups often underrepresented in earlier prevention trials).

This is one of those rare innovations that is not only scientifically compelling, but also operationally transformative.

2. Semaglutide for MASH: metabolic disease finally meets disease-modifying therapy

The Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis (MASH) represents a milestone for hepatology and internal medicine. For years clinicians have watched the burden of MASH escalate, with virtually no approved pharmacologic option capable of improving histology.

In 2025, that changed. Semaglutide, already familiar to diabetologists and obesity specialists, demonstrated significant improvements in hepatic inflammation and steatohepatitis in a rigorously designed NEJM trial.
We now have early evidence of a disease-modifying effect, with possible implications for fibrosis progression.

Combined with its cardiometabolic benefits, semaglutide has evolved into a multisystem therapeutic tool - an unusual and welcome development in chronic metabolic disease.

3. CRISPR “n=1”: personalised gene editing moves from concept to clinic

If one discovery embodies the new frontier of precision medicine, it is the first documented case of in vivo gene editing tailored to a single patient. Published in the New England Journal of Medicine, the case demonstrates something unprecedented: within months, clinicians and researchers designed, validated, and delivered a CRISPR-based therapy to treat a fatal metabolic disorder in a child.

For geneticists and pediatricians, the implications are profound. Beyond the inspiring clinical response, the case provides a blueprint for what “n=1 therapeutics” may look like in the future - tightly regulated, rapidly manufactured, disease-specific interventions.

It is difficult to overstate how radically this could reshape care for ultra-rare diseases.

4. Xenotransplantation reaches functional milestones

Organ shortage remains one of the most intractable challenges in medicine. The 2025 report in Nature documenting 61 days of function in a pig-to-human decedent kidney transplant marks a genuine step forward.
Although these results were obtained in a decedent model, the depth of physiological and immunological detail provided (including filtration capacity, metabolic regulation, and characterisation of rejection pathways) adheres to the highest scientific standards.

For nephrologists and transplant surgeons, this is not hype; it is a signal that xenotransplantation may one day provide a sustainable solution to organ scarcity. Careful ethical, immunologic, and regulatory work remains ahead, but the direction is now clearer.

5. Therapies of the eye and skin: cell and gene therapy enter everyday practice

A particularly encouraging aspect of 2025 is the clinical maturity of advanced therapies outside oncology.

In ophthalmology, the NT-501 CNTF-secreting implant (now approved as Encelto) demonstrated neuroprotective benefit in macular telangiectasia type 2, a condition with few options. The trial published in Ophthalmology strengthens the concept of in vivo “biological factories” capable of locally releasing therapeutic factors over months to years.

In dermatology, autologous gene-corrected keratinocytes for recessive dystrophic epidermolysis bullosa (RDEB) reached regulatory approval supported by long-term safety data. These two examples show that cell and gene therapy are no longer niche technologies confined to academic centres: they are becoming part of real-world clinical practice.

6. Engineered heart tissue: towards regenerative cardiology

Cardiology may be on the brink of its own regenerative revolution. The Nature study demonstrating successful engraftment and functional integration of engineered heart muscle in rhesus macaques provides a roadmap for treating heart failure in ways previously unimaginable.

Unlike earlier attempts, the 2025 data indicate durable vascularisation, electromechanical coupling, and improved cardiac performance.

Although human application remains limited to compassionate-use cases, the scientific trajectory is promising. For clinicians managing heart failure, a condition with rising prevalence and limited restorative therapies, this represents a hopeful horizon.

7. Genetic resilience: a paradigm shift in Alzheimer’s research

In 2025, the comprehensive review by Marino et al. synthesized emerging data on protective genetic variants against Alzheimer’s disease, both in sporadic cases and in families carrying high-penetrance mutations.

Such variants - in genes including APOE, RELN, TREM2 and others - modulate pathways related to lipid transport, synaptic function, immune homeostasis and tau/phosphorylation control. The implication for clinicians and researchers is striking: rather than targeting amyloid or tau clearance alone, future therapies could aim to mimic or enhance these endogenous protective mechanisms, opening a complementary strategy centered on disease resilience. With dementia incidence rising worldwide, this shift from “risk management” to “resilience enhancement” could revolutionize preventive neurology.

8. Interception of pancreatic carcinogenesis

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid tumors, largely because it is diagnosed too late. The 2025 Cancer Research study showing that FGFR2 abrogation can halt progression of KRAS-driven precancerous lesions is therefore notable.

No clinician would interpret this as a ready-to-use preventive therapy, but as a mechanistic proof it is highly valuable: it identifies a modifiable molecular pathway in a tumour type traditionally considered biologically unforgiving.

Should these findings translate to human models, we may one day talk about “interceptive oncology” even for PDAC, a paradigm shift.

9. Self-collected HPV samples: screening becomes more accessible and scalable

In 2025, the American Cancer Society updated its cervical cancer screening guideline to include vaginal self-sampling for HPV as an acceptable option. This shift is grounded in robust evidence: multiple studies show that self-collected samples reach sensitivity levels comparable to clinician-collected swabs.

For gynecologists and primary-care physicians, the significance is practical: self-collection may reach individuals who traditionally decline screening, reducing disparities and improving early detection.

This is a case where innovation is not technological but organisational, and the impact may be substantial.

10. AI-designed antibiotics: a long-awaited answer to antimicrobial resistance

Among the most intellectually exciting papers of the year is the Cell publication describing a generative deep-learning pipeline for de novo antibiotic design. Unlike earlier machine-learning approaches, this system integrates target prediction, compound generation, and mechanistic analysis.

While still preclinical, the identification of novel structures with in vitro activity against resistant pathogens marks a meaningful advance. For infectious-disease specialists, it signals that AI may contribute not merely to diagnostics, but to the creation of therapeutics — an area where drug discovery has stagnated for decades.

What 2025 signals for the next decade of medicine

What distinguishes 2025 is not the volume of new findings, but their diversity and credibility. Several breakthroughs - lenacapavir, semaglutide, gene and cell therapies - are ready to influence care today. Others - engineered tissues, xenotransplantation, AI-generated antibiotics - map the contours of medicine’s next decade.

For clinicians, understanding these trajectories is not academic curiosity: it is preparation. The future of practice will demand fluency in genetics, metabolism, regeneration, and computational biology. If 2025 teaches us anything, it is that these domains are no longer separate. They are converging, and our patients will experience the impact long before the decade ends.

These ten breakthroughs are not meant to be exhaustive, and many colleagues may have encountered other advances they consider just as influential. We invite you to share in the comments which discoveries of 2025 you believe will have the greatest impact on patient care in the years ahead.

Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sánchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O; PURPOSE 2 Study Team. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2025 Apr 3;392(13):1261-1276. doi: 10.1056/NEJMoa2411858. Epub 2024 Nov 27. PMID: 39602624.
Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V; ESSENCE Study Group. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 5;392(21):2089-2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30. PMID: 40305708.
Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, Hacker JL, Hsu A, Silverstein RA, Hille LT, Ogul AN, Robinson-Garvin NA, Small JC, McCague S, Burke SM, Wright CM, Bick S, Indurthi V, Sharma S, Jepperson M, Vakulskas CA, Collingwood M, Keogh K, Jacobi A, Sturgeon M, Brommel C, Schmaljohn E, Kurgan G, Osborne T, Zhang H, Kinney K, Rettig G, Barbosa CJ, Semple SC, Tam YK, Lutz C, George LA, Kleinstiver BP, Liu DR, Ng K, Kassim SH, Giannikopoulos P, Alameh MG, Urnov FD, Ahrens-Nicklas RC. Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease. N Engl J Med. 2025 Jun 12;392(22):2235-2243. doi: 10.1056/NEJMoa2504747. Epub 2025 May 15. PMID: 40373211.
Montgomery RA, Stern JM, Fathi F, Suek N, Kim JI, Khalil K, Vermette B, Tatapudi VS, Mattoo A, Skolnik EY, Jaffe IS, Aljabban I, Eitan T, Bisen S, Weldon EP, Goutaudier V, Morgand E, Mezine F, Giarraputo A, Boudhabhay I, Bruneval P, Sannier A, Breen K, Saad YS, Muntnich CB, Williams SH, Zhang W, Kagermazova L, Schmauch E, Goparaju C, Dieter R, Lawson N, Dandro A, Fazio-Kroll AL, Burdorf L, Ayares D, Lorber M, Segev D, Ali N, Goldfarb DS, Costa V, Hilbert T, Mehta SA, Herati RS, Pass HI, Wu M, Boeke JD, Keating B, Mangiola M, Sommer PM, Loupy A, Griesemer A, Sykes M. Physiology and immunology of pig-to-human decedent kidney xenotransplant. Nature. 2025 Nov 13. doi: 10.1038/s41586-025-09847-6. Epub ahead of print. PMID: 41233546.
Chew EY, Gillies M, Jaffe GJ, Gaudric A, Egan C, Constable I, Clemons T, Aaberg T, Manning DC, Hohman TC, Bird A, Friedlander M; MacTel CNTF NTMT-03 Research investigators. Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2. NEJM Evid. 2025 Aug;4(8):EVIDoa2400481. doi: 10.1056/EVIDoa2400481. Epub 2025 Jul 22. PMID: 40693847.
Jebran AF, Seidler T, Tiburcy M, Daskalaki M, Kutschka I, Fujita B, Ensminger S, Bremmer F, Moussavi A, Yang H, Qin X, Mißbach S, Drummer C, Baraki H, Boretius S, Hasenauer C, Nette T, Kowallick J, Ritter CO, Lotz J, Didié M, Mietsch M, Meyer T, Kensah G, Krüger D, Sakib MS, Kaurani L, Fischer A, Dressel R, Rodriguez-Polo I, Stauske M, Diecke S, Maetz-Rensing K, Gruber-Dujardin E, Bleyer M, Petersen B, Roos C, Zhang L, Walter L, Kaulfuß S, Yigit G, Wollnik B, Levent E, Roshani B, Stahl-Henning C, Ströbel P, Legler T, Riggert J, Hellenkamp K, Voigt JU, Hasenfuß G, Hinkel R, Wu JC, Behr R, Zimmermann WH. Engineered heart muscle allografts for heart repair in primates and humans. Nature. 2025 Mar;639(8054):503-511. doi: 10.1038/s41586-024-08463-0. Epub 2025 Jan 29. PMID: 39880949; PMCID: PMC11903342.
Marino C, Malotaux V, Giudicessi A, Aguillon D, Sepulveda-Falla D, Lopera F, Quiroz YT. Protective genetic variants against Alzheimer's disease. Lancet Neurol. 2025 Jun;24(6):524-534. doi: 10.1016/S1474-4422(25)00116-4. PMID: 40409316; PMCID: PMC12614636.
Tonelli C, Deschênes A, Gaeth VA, Jensen A, Vithlani N, Yao MA, Zhao Z, Park Y, Tuveson DA. FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development. Cancer Res. 2025 Jun 2;85(11):1960-1977. doi: 10.1158/0008-5472.CAN-24-4576. PMID: 40170241; PMCID: PMC12169444.
Phillips SA, Denoël S, Wentzensen N, Arbyn M. Accuracy of HPV Self-Collection Compared with Clinician-Collected HPV Testing and Cytology: A Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2025 Sep 2;34(9):1467-1471. doi: 10.1158/1055-9965.EPI-25-0362. PMID: 40643571.
Krishnan A, Anahtar MN, Valeri JA, Jin W, Donghia NM, Sieben L, Luttens A, Zhang Y, Modaresi SM, Hennes A, Fromer J, Bandyopadhyay P, Chen JC, Rehman D, Desai R, Edwards P, Lach RS, Aschtgen MS, Gaborieau M, Gaetani M, Palace SG, Omori S, Khonde L, Moroz YS, Blough B, Jin C, Loh E, Grad YH, Saei AA, Coley CW, Wong F, Collins JJ. A generative deep learning approach to de novo antibiotic design. Cell. 2025 Oct 16;188(21):5962-5979.e22. doi: 10.1016/j.cell.2025.07.033. Epub 2025 Aug 14. PMID: 40816267.